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ABSTRACT
Objective. To synthetize the scientific evidence on the association between serum lipids
and premature mortality in Latin America (LA).
Methods. Five data bases were searched from inception without language restrictions:
Embase, Medline, Global Health, Scopus and LILACS. Population-based studies
following random sampling methods were identified. The exposure variable was lipid
biomarkers (e.g., total, LDL- or HDL- cholesterol). The outcome was all-cause and
cause-specific mortality. The risk of bias was assessed following the Newcastle-Ottawa
criteria. Results were summarized qualitatively.
Results. The initial search resulted in 264 abstracts, five (N = 27,903) were included
for the synthesis. Three papers reported on the same study from Puerto Rico (baseline
in 1965), one was from Brazil (1996) and one from Peru (2007). All reports analysed
different exposure variables and used different risk estimates (relative risks, hazard
ratios or odds ratios). None of the reviewed reports showed strong association between
individual lipid biomarkers and all-cause or cardiovascular mortality.
Conclusion. The available evidence is outdated, inconsistently reported on several lipid
biomarker definitions and used differentmethods to study the long-termmortality risk.
These findings strongly support the need to better ascertain themortality risk associated
with lipid biomarkers in LA.
Subjects Cardiology, Epidemiology, Global Health, Public Health
Keywords Dyslipidaemias, Cholesterol, Survival, Latin America
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INTRODUCTION
An unfavourable serum lipid profile such as increased total cholesterol or LDL-
cholesterol is an important determinant of cardiovascular diseases causing large negative
health consequences in low- and middle-income countries (LMICs) (GBD 2017 Risk
Factor Collaborators, 2018; Global Burden of Metabolic Risk Factors for Chronic Diseases
Collaboration, 2014). Understanding the long-term effects of lipids on health is relevant to
support the current national and international guidelines which provide recommendations
for their management to achieve good cardiovascular health (Catapano et al., 2016;
Grundy et al., 2019; NICE, 2014). In addition, many risk scores for primary prevention
of cardiovascular diseases include lipid measurements as one of their predictors (Conroy
et al., 2003; D’Agostino Sr et al., 2008; Goff Jr et al., 2014; Conroy et al., 2003; D’Agostino
Sr et al., 2008). Despite the relevance of serum lipids and use in clinical medicine, the
epidemiological research is still limited in LMICs including Latin America (LA) (Ponte-
Negretti et al., 2017).
Epidemiological studies have reported inconsistent findings about the association
between lipids and premature cardiovascular mortality (Di Angelantonio et al., 2009;
Lewington et al., 2007). The Prospective Studies Collaboration reported a lower hazard of
death due to ischaemic heart disease for each one mmol/L reduction of total cholesterol
(Lewington et al., 2007). However, the evidence of an association between serum lipids and
cerebrovascular disease mortality was less consistent in their study (Lewington et al., 2007).
Furthermore, the Emerging Risk Factor Collaboration revealed a higher hazard of death
due to coronary heart diseases for people with increased cholesterol and LDL-cholesterol
levels and those with decreased HDL-cholesterol (Di Angelantonio et al., 2009). Again, the
evidence was less conclusive when the main outcome was ischaemic stroke mortality (Di
Angelantonio et al., 2009). Other prospective studies have reported that the association
between total cholesterol and stroke mortality varies according to stroke sub-type (Yi
et al., 2018). Moreover, a study including people aged 60 years and above reported a
reduced mortality between increased serum total cholesterol and all-cause mortality,
most likely due to a high number of non-cardiovascular deaths (Liang, Vetrano & Qiu,
2017); similarly, LDL-cholesterol seems to have a negative correlation with mortality in
people 60 years old and above (Ravnskov et al., 2016). These inconsistent findings have
not included populations in LA, where different distribution of cholesterol levels, health
profiles and access to healthcare or pharmaceutical treatment (Atun et al., 2015; Cotlear et
al., 2015; Farzadfar et al., 2011), exist. Therefore, summarizing studies on the association
between lipid biomarkers and mortality in LA populations may complement international
evidence, as well as provide valuable information for the development of local guidelines for
clinicians and health policy makers. The objective of this study was to synthetize through
a systematic review the current scientific evidence on the association between serum lipids
and premature mortality in LA.
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METHODS
Protocol
We conducted a systematic review of the literature following the PRISMA guidelines
(Supplemental Information, pp. 02–04) (Liberati et al., 2009). The protocol was registered
at PROSPERO (CRD42019120491). Epidemiological studies in adults assessing the
association between lipid biomarkers (e.g., total cholesterol) and all-cause as well as cause-
specific mortality in LA populations were aimed for. Although no specific comparator
was sought, we aimed to study the mortality risk of impaired levels of lipid biomarkers in
comparison with recommended levels or per unit change in mg/dL or mmol/L.
Eligibility criteria
We searched for observational prospective cohort studies without any language restrictions
regardless of publication time. The study population comprised of individuals from all LA
countries. Studies addressing LA people in foreign countries or foreigners in LA countries
were excluded. We aimed for population-based studies which had followed a random
sampling technique to select the study population. Hospital-based studies, convenient
samples or participants selected based on a diagnosis (e.g., patients with diabetes) or
risk factor (e.g., obese individuals) were excluded. The exposure of interest was any lipid
biomarker, including but not limited to total cholesterol, HDL-cholesterol, LDL-cholesterol
or triglycerides.
Information sources
The search was conducted in five data bases: Embase, Global Health and Medline through
Ovid, Scopus and LILACS. The search was conducted on December 21st, 2018. No
additional sources of scientific information were considered. The search strategy used in
these search engines is available in the Supplemental Information, pp. 05–07.
Study selection
The search results were downloaded and compiled in EndNote, where duplicates were
identified and excluded. A second search for duplicates was conducted online with Rayyan
(Ouzzani et al., 2016). Screening of titles and abstracts was performed by two independent
reviewers (RMC-L, LA-F) following the selection criteria above detailed; discrepancies
were solved by consensus between them. The full text of the selected reports was studied
in detail by the same reviewers, also following the above explained criteria; discrepancies
were solved by consensus as well. The two stages of the selection process were conducted
with the online tool Rayyan (Ouzzani et al., 2016).
When multiple reports were found for one study, the following algorithm was followed
to select one report for inclusion in qualitative synthesis: (i) if they reported on different
outcomes (e.g., all-cause and cardiovascular mortality), then all the reports were included;
and (ii) the report which analysed the longer follow-up time was included.
Data collection
With the final list of selected reports, information was extracted onto an Excel sheet
developed by the authors before data collection started and was not modified afterwards;
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this form collected similar information as in Ravnskov et al. (2016). The extraction form
included information about the study (authors, year of publication, country), about the
study population (sample size, age and sex ratio at baseline, follow-up time), and about
the distribution of lipid biomarkers including mean and/or prevalence according to data
availability in each selected report. Moreover, to assess the mortality risk, risk estimates
such as relative risks or hazard ratios were extracted according to what was reported in the
original paper. Data extractionwas conducted by one reviewer (RMC-L) and independently
verified by another one (AB-O); discrepancies were solved by consensus between them.
Risk of bias in individual studies
The Newcastle-Ottawa Scale was used to assess the risk of bias in the selected reports
(Wells et al., 2019). The risk of bias assessment was conducted by one reviewer (LA-F)
and independently verified by another one (AB-O). If there were discrepancies, these were
solved by consensus between these reviewers.
Summary measures
We conducted a qualitative synthesis, and where relevant the risk estimates as described
in the original report were summarized. No quantitative synthesis such as a meta-analysis
was possible to conduct because of the few retrieved reports, which also exhibited large
heterogeneity in the lipid biomarkers assessed, outcomes, and statistical methods.
Ethical considerations
This project was classified as non-human subject research. This is a systematic review of
published and open information where no human subjects participated. Approval from an
IRB/ethics committee was not necessary.
RESULTS
Study selection
After duplicates were removed, 264 titles and abstracts were screened for eligibility, and 23
were further studied in detail. Threemanuscripts were excluded after applying the exclusion
criteria: (Cruz-Vidal et al., 1983; Marafon et al., 2003; Sorlie & Garcia-Palmieri, 1990) two
studies were excluded because a newer report was available using the same data (Cruz-Vidal
et al., 1983;Marafon et al., 2003), and one because the assessed outcome was the same as in
another report of the same data (Sorlie & Garcia-Palmieri, 1990). Finally, five reports were
included for qualitative synthesis (N = 27,903) (Crespo et al., 2002; Garcia-Palmieri et al.,
1981; Garcia-Palmieri et al., 1988; Lazo-Porras et al., 2016; Werle et al., 2011). Of the five
selected reports for qualitative synthesis, three were using the same project (Puerto Rico
Heart Health Program) (Crespo et al., 2002; Garcia-Palmieri et al., 1981; Garcia-Palmieri et
al., 1988) and two were independent studies in Peru (Lazo-Porras et al., 2016) and Brazil
(Werle et al., 2011). Figure 1 presents the number of studies at each stage of the selection
process and the reasons for exclusion.
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Figure 1 Flow-chart of the selection process.
Full-size DOI: 10.7717/peerj.7856/fig-1
Study characteristics
Three reports collected baseline data in 1965 (Crespo et al., 2002; Garcia-Palmieri et
al., 1981; Garcia-Palmieri et al., 1988), one in 1996 (Werle et al., 2011) and one in 2007
(Lazo-Porras et al., 2016). Four reports included middle-aged adults (Crespo et al., 2002;
Garcia-Palmieri et al., 1981; Garcia-Palmieri et al., 1988; Lazo-Porras et al., 2016), while
one studied the elderly (mean age= 83.6 years) (Werle et al., 2011). Three reports included
only men (Crespo et al., 2002; Garcia-Palmieri et al., 1981; Garcia-Palmieri et al., 1988), in
one report men accounted for almost half of the study population (47.2%) (Lazo-Porras
et al., 2016), and in other report the proportion of men was smaller (36.4%) (Werle et al.,
2011). The follow-up time varied from 5 to 12 years (Crespo et al., 2002; Garcia-Palmieri
et al., 1981; Garcia-Palmieri et al., 1988; Lazo-Porras et al., 2016; Werle et al., 2011). The
outcome of the three reports from Puerto Rico were all-cause mortality (Crespo et al.,
2002), cardiovascular disease mortality (Garcia-Palmieri et al., 1988), and cancer mortality
(Garcia-Palmieri et al., 1981). Werle et al. (2011) and colleagues studied cardiovascular
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disease mortality, whereas Lazo-Porras et al. (2016) assessed all-cause and cardiovascular
mortality. Details about the study characteristics are shown in Table 1.
Lipid biomarkers at baseline
Table 2 shows themeans andprevalence estimates for the studied lipid biomarkers across the
reports. The selected reports used different classifications to present prevalence estimates.
For example, Lazo-Porras et al. (2016) reported the prevalence of low HDL-cholesterol
(56.5%), isolated low HDL-cholesterol (36.5%), high non-HDL-cholesterol (91.6%), low
HDL-cholesterol with triglycerides ≥200 mg/dL (15.0%), and low HDL-cholesterol with
LDL-cholesterol >160 mg/dL (2.0%). Crespo and colleagues showed the prevalence of
total cholesterol <200 mg/dL (50.9%), 200–239 mg/dL (33.2%) and ≥240 mg/dL (15.9%)
(Crespo et al., 2002).
Other studies reported mean values. For example, Werle et al. (2011) showed that the
mean total cholesterol was 211.6 (SD: 47.4) mg/dL, HDL-cholesterol had a mean of 45.5
(SD: 12.6) mg/dL, the mean LDL-cholesterol was 139.1 (SD: 42.5) mg/dL, and the mean
for triglycerides was 137.2 (SD: 65.6) mg/dL. Werle et al. also reported on ApoA-I and
ApoB-100, with means of 165.4 (SD: 33.7) mg/dL and 87.5 (SD: 21.0) mg/dL, respectively
(Werle et al., 2011).
Mortality risk
Table 3 (Supplemental Information p. 08) summarizes the risk estimates as provided
by each report. All selected reports analysed different exposure variables not allowing to
conduct a meta-analysis. In addition, the reports used different risk estimates including
relative risks (RR), hazard ratios (HR) and odds ratios (OR).
Lazo-Porras et al. (2016) studied all-cause mortality based on a composite three-level
exposure variable: normal HDL-cholesterol vs isolated low HDL-cholesterol [HDL-c<40
mg/dL in men and <50 mg/ dL in women without hypertriglyceridemia and LDL <160
mg/dL] and non-isolated low HDL-cholesterol [HDL-c<40 mg/dL in men and <50 mg/dL
in women accompanied by hypertriglyceridemia and/or LDL ≥ 160 mg/dL]; the first level
was the reference category whereas the second and third exhibited a RR of 1.11 (95% CI
[0.49–2.51]) and 0.82 (95% CI [0.21–3.15]), respectively (Lazo-Porras et al., 2016). Crespo
and colleagues also studied all-cause mortality in a cohort of men, showing 3% higher
mortality risk in people with high total cholesterol in comparison to their peers with total
cholesterol in the normal range; in addition, there was not higher risk when the latter group
was compared with people with borderline high total cholesterol (Crespo et al., 2002).
Werle and colleagues studied cardiovascular mortality associated with one-unit change
(mg/dL) in LDL-cholesterol (HR = 1.00, 95% CI [0.99–1.01]), HDL-cholesterol (HR
= 1.01, 95% CI [0.97–1.05]), and Apo-A (HR = 0.99, 95% CI [0.98–1.01]) (Werle et
al., 2011). Garcia-Palmieri’s team reported on cardiovascular mortality too, though the
magnitude of the effect was very small (Garcia-Palmieri et al., 1988).
Garcia-Palmieri et al. (1988) used cancer mortality as main outcome reporting the OR
for one-unit change (mg/dL) in total cholesterol by urban/rural location and age group.
For example, in rural men aged 45–54 years, the OR was 0.54 (p< 0.05) for each mg/dL
increase in total cholesterol (Garcia-Palmieri et al., 1981).
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Table 1 Characteristics of the selected reports.
Author Country Baseline
year
Baseline
sample
size
Baseline
age
Baseline
%men
Follow-up
time
Body
mass
index
(mean)
Smoker Systolic
blood
pressure
(mean)
Glucose
(mean)
Hypertension Diabetes
Lazo-Porras et al. (2016) Peru
(Lima, Ayacucho)
2007–08 988 48 (SD: 12) 47 ∼5 years 33.3%* 3.3% NA NA NA NA
Werle et al. (2011) Brazil
(Veranopolis)
1996 193 84 (SD: 3.3) 36 ∼11 years 26.7 6.7% 168 5.4 93% 17.6%
Garcia-Palmieri et al. (1981) Puerto Rico 1965 8,793 45–64 100 ∼8 years NA 7.6 U 133 5.4 NA NA
Crespo et al. (2002) Puerto Rico 1965 9,136 35–79 100 ∼12 years 49.7%* 34.2% ξ NA NA 35.4% NA
Garcia-Palmieri et al. (1988) Puerto Rico 1965 8,793 45–64 100 ∼12 years NA NA NA NA NA NA
Notes.
aOverweight prevalence. U number smoked per day. ξ non-smokers.
SD, standard deviation; NA, not available.
For Garcia-Palmieri’s and Crespo’s works the age is given as ranges. Glucose estimates are given as mmol/l.
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Table 2 Baseline lipid profile as in the summarised reports.
Author Baseline Total Cholesterol
(mg/dl)
If prevalence,
what was the
definition?
Baseline HDL (mg/dl) If prevalence,
what was the
definition?
Baseline LDL
(mg/dl)
If prevalence,
what was
the definition?
Baseline Triglycerides
(mg/dl)
If prevalence,
what was
the definition?
Baseline Other
(specify)
Mean (specify) If prevalence,
what was
the definition?
Mean
(SD)
Prevalence
(%)
Mean
(SD)
Prevalence
(%)
Mean
(SD)
Prevalence
(%)
Mean
(SD)
Prevalence
(%)
Mean
(SD)
Prevalence
(%)
56.5 Low HDL-cholesterol
(HDL-cholesterol <40
in men and <50 in
women)
3.0 LDL-cholesterol >160 4.0 Triglycerides ≥200 3.0 LDL-cholesterol
>160, triglycerides
≥200 & low HDL-
cholesterol
36.5 Isolated low HDL-
cholesterol
2.0 LDL-cholesterol >160
& triglycerides ≥200
91.6 High non-HDL-
cholesterol
15.0 Low HDL-cholesterol
and triglycerides
≥200
Lazo-
Porras
2.0 Low HDL-cholesterol
& LDL-cholesterol
>160
211.6
(SD: 47.4)
45.5
(SD: 12.6)
139.1
(SD: 42.5)
137.2
(SD: 65.6)
165.4
(SD: 33.7)
ApoA-I
(mg/dL)
Werle
87.5 (SD: 21.0) ApoB-100 (mg/dL)
Garcia-Palmieri 202.4 152.0
50.9 <200
33.2 200-239Crespo
15.9 ≥240
202.06
Garcia-
Palmieri
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Table 3 Risk estimates of lipid biomarkers onmortality as in the summarised reports.Garcia-Palmieri et al. (1981) reported multiple regression coefficients (‘‘The lo-
gistic function was used to model the relationship between cancer mortality and serum cholesterol’’), so that the OR herein reported corresponds to the exponential func-
tion of the coefficients in the manuscript. Crespo et al. (2002) - The authors did not provide risk estimates; the IRR herein reported corresponds to the relation between
crude death rates among people with high cholesterol (crude death rate= 16.3%), borderline high blood cholesterol (crude death rate= 15.5%) and desirable cholesterol
(crude death rate= 15.8%). For example, 15.8/16.3∼0.97. Where available, the risk estimates herein summarized correspond to the adjusted models reported in the orig-
inal reports.
Author Exposure definition All-cause mortality Cardiovascular mortality Other causes of death assessed
Risk
estimate
lower
IC
upper
IC
Risk
estimate
lower
IC
upper
IC
Risk
estimate
lower
IC
upper
IC
Cause?
Normal HDL vs isolated low HDL
[HDL-c <40 mg/dL in men and
<50 mg/ dL in women without
hypertriglyceridemia and LDL
<160 mg/dL]
RR= 1.11 0.49 2.51 RR= 0.45 0.05 4.24
Lazo-Porras et al. (2016)
Normal HDL vs non-isolated low
HDL [HDL-c <40 mg/dL in men
and <50 mg/dL in women with
hypertriglyceridemia and/or LDL
≥160 mg/dL]
RR= 0.82 0.21 3.15 RR= 3.67 0.48 28.16
LDL (mg/dL) HR= 1.00 0.99 1.01
HDL (mg/dL) HR= 1.01 0.97 1.05Werle et al. (2011)
ApoA-I (mg/dL) HR= 0.99 0.98 1.01
Serum cholesterol (mg/dL), 45–54
rural men
OR= 0.54 p< 0.05 Cancer
Serum cholesterol (mg/dL), 55–64
rural men
OR= 0.48 p< 0.05 Cancer
Serum cholesterol (mg/dL), 45–54
urban men
OR= 0.78 CancerGarcia-Palmieri et al. (1981)
Serum cholesterol (mg/dL), 55–64
urban men
OR= 1.08 Cancer
Desirable total cholesterol ( <200
mg/dL) vs high total cholesterol
(≥240 mg/dL)
IRR= 0.97
Crespo et al. (2002)
Desirable total cholesterol ( <200
mg/dL) vs borderline high blood
cholesterol (200-239 mg/dL)
IRR= 1.02
Garcia-Palmieri et al. (1988) Serum cholesterol (mg/dL) OR= 0.004 p< 0.05
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Table 4 Risk of bias assessment.
selection Comparability Outcome
Lazo-Porras et al. (2016) FFFF FF FFF
Werle et al. (2011) FFF FF FFF
Garcia-Palmieri et al. (1981) FFF F FFF
Crespo et al. (2002) FFFF FF FF
Garcia-Palmieri et al. (1988) FFF F FFF
Risk of bias
Table 4 presents the summary of the risk of bias assessment, details in Supplemental
Information p. 09. (Lazo-Porras et al., 2016) authored the work with the least risk of bias,
whereas both reports by Garcia-Palmieri (Garcia-Palmieri et al., 1981; Garcia-Palmieri et
al., 1988) showed the highest risk of bias mostly due to the comparability criteria.
A narrative experience
Lazo-Porras et al. (2016) and colleagues studied the residual dyslipidaemic profile and
its impact on mortality. Interestingly, they analysed a cohort of rural dwellers, urban
people and rural-to-urban migrants (Lazo-Porras et al., 2016). These populations have
unique features and these results could still be of interest to other LMICs where internal
migration and urbanization is underway. However, one could argue on the pragmatic
need, implications and applicability of these results in health policy or clinical practice.
Werle et al. (2011) reported on elderly individuals with relatively strong risk estimates.
As aging is an ongoing process in LA and LMICs, these results and their implications among
the oldest old could inform future studies in these populations. Nonetheless, this endeavour
could not provide further arguments to advance the inconsistent findings among elderly
populations, as signalled in the introduction.
Garcia-Palmieri et al. and Crespo et al. analysed a cohort of men starting in 1965,
and studied all-cause, cardiovascular disease and cancer mortality (Crespo et al., 2002;
Garcia-Palmieri et al., 1981; Garcia-Palmieri et al., 1988). This is the largest cohort herein
summarized where outcomes were comprehensively adjudicated; however, because only
men were included, these estimates could not successfully inform clinical practice or public
health for the whole population. Although these authors analysed cardiovascular mortality,
and so did Lazo-Porra’s and Werle’s team (Lazo-Porras et al., 2016;Werle et al., 2011), they
did not look at specific cardiovascular events, e.g., coronary heart disease, ischaemic stroke
or haemorrhagic stroke. Therefore, these reports could not provide additional evidence to
elucidate the inconclusive knowledge signalled in the introduction.
Overall, total cholesterol was the exposure mostly studied, except for Werle’s and
Lazo-Porras’s work, which included LDL-cholesterol and residual dyslipidaemic profile,
respectively (Lazo-Porras et al., 2016; Werle et al., 2011). The effect of total cholesterol
on health outcomes such as mortality, could vary depending on its composition, i.e.,
whether LDL-cholesterol levels are high. Conversely, LDL-cholesterol is a well-stablished
cardiovascular risk factor for which successful pharmacological treatment is available (e.g.,
statins). Unfortunately, prospective evidence on the effect of LDL-cholesterol is still scarce
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in LA, though much needed to inform clinical practice as well as resources and treatment
allocation.
DISCUSSION
Summary of evidence
This systematic review of the literature in LA did not reveal scientific evidence on an
association between unfavourable serum lipid biomarkers and premature mortality in the
general population. Furthermore, the definitions used to categorize lipid biomarkers were
inconsistent across reports. In addition, only one study was conducted within the last ten
years. Overall, our findings call to either conduct new cohort studies or use available ones
to systematically estimate the mortality risk associated with lipid profiles, using consistent
metrics and clinically relevant definitions. Thus, there is a need to study the long-term
effects of lipid profiles as this will provide evidence to inform local clinical practice, health
policy and priority setting for LA.
Limitations of the review
Even though we conducted a comprehensive literature search, including a LA-based search
engine (LILACS), we did not systematically search grey literature such as conference
abstracts. We argue that, even if these sources had provided additional references, these
would contain probably limited information.
Although some of the selected studies reported on relevant lipid biomarkers such as LDL-
cholesterol, they failed to analyse clinically relevant definitions. For example, Lazo-Porras
and colleagues reported on several combinations of lipidmetrics (e.g., lowHDL-cholesterol
and triglycerides≥200mg/dL), but did not report on high LDL-cholesterol, which happens
to be the lipid mainly targeted by pharmacological treatment for cardiovascular prevention
(Collins et al., 2016; Grundy et al., 2019; Yusuf et al., 2016).
Results in context
Previous large individual-level meta-analysis have assessed mortality risk associated with
one unit change in lipids (Di Angelantonio et al., 2009; Lewington et al., 2007). In this
systematic review, the most recent study addressing this exposure was the work by Werle
et al., whom reported that there was no strong evidence of higher risk (Werle et al.,
2011). Noteworthy, the study population in Werle’s work had a mean age of 83 years
(Werle et al., 2011). Therefore, this finding is consistent with previous reports where the
magnitude of the risk estimates would also decrease with age (Lewington et al., 2007).
Other recent systematic review studying people aged 60 years and above, also reported
an inverse association between LDL-cholesterol and all-cause mortality (Ravnskov et al.,
2016). Despite this evidence, the use of statins in elderly still seems to reduce cardiovascular
mortality (Cholesterol Treatment Trialists’ Collaboration, 2019). Evidence in LA regarding
young adults, middle-aged adults and elderly, is still limited to draw conclusions and
formulate strong recommendations. For the time being, international guidelines should be
followed along with clinical reasoning and shared decision making.
The INTERHEART, a case-control global endeavour studying myocardial infarction,
reported that the association between this cardiovascular outcome and total cholesterol
Carrillo-Larco et al. (2019), PeerJ, DOI 10.7717/peerj.7856 11/19
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Figure 2 Call to action for Latin America in research and policy.
Full-size DOI: 10.7717/peerj.7856/fig-2
as well as non-HDL cholesterol was small in LA, in comparison to other world regions
(McQueen et al., 2008). Although this is a large and relevant scientific contribution, the
results have the limitations of any case-control study. In addition, this was conducted almost
ten years ago. Their findings deserve further verification with a stronger study design and
more recent observations, to provide robust evidence that can be introduced in clinical
and public health practice and that can account for the current trends in cardio-metabolic
risk factors.
Relevance for LA
Strong scientific evidence is needed to develop successful policies, inform resources
allocation, and advance clinical practice. Regarding lipid biomarkers and its associated
mortality risk, much research is needed. A proposed call to action for LA is presented in
Fig. 2.
Despite limited scientific research in the field of lipid biomarkers in LA in general, there is
a growing interest about this health profile in the clinical and public health communities of
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LA (Ponte-Negretti et al., 2017). This interest has led to the development of local guidelines
onmanagement of hyperlipidaemias in some countries such asMexico (Secretaria de Salud,
2013) and Colombia (Sistema General de Seguridad Social en Salud Colombia, 2014; Sistema
General de Seguridad Social en Salud Colombia, 2014) among others (Caja Costarricense de
Seguridad Social, 2004; Sociedad Argentina de Cardiologia, 2018; Sociedad Uruguaya de
Aterosclerosis, 1998; (Caja Costarricense de Seguridad Social, 2004; Sociedad Argentina de
Cardiologia, 2018; Sociedad Uruguaya de Aterosclerosis, 1998). Analysing whether these
local guidelines are in accordance with international recommendations or current scientific
evidence is beyond the scope of this work, but definitely merits a close inspection.
To the best of our knowledge, no relevant international organization has set goals, targets
or health and research policies for the management and control of lipid biomarkers or
dyslipidaemias in LA. Although a group of practitioners and researchers of LA has published
a regional consensus highlighting key features of lipid profiles in LA (Ponte-Negretti et al.,
2017), further scientific evidence is needed for this momentum to foster research, policy
and clinical practice. In addition to a consensus, additional pragmatic steps are needed
(Ponte-Negretti et al., 2017). For example, we recommend that this group (Ponte-Negretti
et al., 2017) or other relevant professional or governmental body, issues a list of basic
metrics that should be included and reported in any research studying lipid biomarkers in
LA. These measures may allow to conduct meta-analysis and to estimate other population
health metrics benefiting of consistent and comparable lipid-related metrics throughout
LA.
Most of the risk estimates used in the studies was total cholesterol. This lipid biomarker,
although relevant and inexpensive, does not allow to identify whether a reduction of
LDL-cholesterol or an increase of HDL-cholesterol is needed. A key determinant of lipid
fraction is diet. Certain foods will increase LDL-cholesterol whilst others will improve
HDL-cholesterol and viceversa (Forouhi et al., 2018; Schwingshackl et al., 2018). Because
LA shows great variability in diet patterns between and within countries, this could define
higher/lower levels of different lipid fractions. Future studies should try to ascertain lipid
fractions in addition to total cholesterol.
Other determinants of lipid profiles are weight status and physical activity, whereby
obesity increases LDL-cholesterol and decreases HDL-cholesterol whilst physical activity
reduces LDL-cholesterol. Overweight and obesity have dramatically increased across LA in
the last decades (NCD Risk Factor Collaboration, 2017). Also, a global analysis reported that
women in LA have one of the largest prevalence estimates of physical inactivity (Guthold
et al., 2018). Although these risk factors need to be addressed on their own, these alarming
trends also call to improve the study of lipid biomarkers in LA at the general population
level. In this line, government and international agencies could potentiate national surveys
to also collect lipid biomarkers such as in Mexico (Aguilar-Salinas et al., 2010), Ecuador
(Freire et al., 2014) and Chile (Margozzini & Passi, 2018). If in the next years these could be
linked to death registries so that individual risks could be estimated, a major step forward
in the study of lipid biomarkers would be achieved.
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CONCLUSIONS
Todate, it is not possible to ascertain the association between lipid biomarkers andmortality
risk in LA. The available evidence is outdated, and the definitions of lipid biomarkers are
inconsistent. In addition, different methods were used to measure the long-term mortality
risk in LA populations. These findings strongly suggest conducting larger studies within
the LA population to get valuable risk estimates of the associations between serum lipids
and premature mortality.
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